期刊档案 · Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Pharmacological Research Modern Chinese Medicine
ISSN 2667-1425 · Elsevier · Netherlands
Pharmacological Research Modern Chinese Medicine 影响因子 12.2（官网公布），钻石开放获取（无 APC），免版面费，出版商公布投稿到接收约 64 天，2025 年发文 166 篇，Scopus 收录。
研究范围
研究范围与定位
Pharmacological Research Modern Chinese Medicine 由 Elsevier 出版。按 OpenAlex 近年发文统计，该刊主要发表 Pharmacological Effects of Natural Compounds、Traditional Chinese Medicine Analysis、Natural Antidiabetic Agents Studies 等主题的论文，这 3 个主题约占 26.5%，主导子领域为 Complementary and alternative medicine。（根据 OpenAlex 主题统计与中科院分区数据生成）
Affiliated with the 'Chinese Pharmacological Society', he journal Pharmacological Research - Modern Chinese Medicine (PRMCM) publishes articles reporting on advances in our comprehension of mechanism and safety in experimental pharmacology and clinical efficacy and safety of pharmacologically active substances, including compound prescriptions, utilized in Traditional Chinese Medicine applying modern scientific research methods. Studies reporting also on the mechanisms of actions of the active substance(s) investigated are encouraged.Reports must be on standardized preparations in which the ingredients are defined; elucidation of which are the active principles and which pathways they trigger is encouraged but not mandatory.The diseases investigated must be classified according to the WHO International Classification of Diseases version 11. Negative results will be considered.The Journal will not consider articles utilizing material from endangered species as categorized by the International Union for Conservation of Nature.Pharmacological Research - Modern Chinese Medicine (PRMCM) is an independent companion journal and a spin-off from Pharmacological Research (Pharmacol Res). It is part of the Pharmacological Research Family of Journals. PRMCM has an independent editorial team and will be indexed differently.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
主编 Guanhua Du出版商官网
编委会国家分布：中国大陆 85 位（约 85%）；主要国家 中国 85、中国澳门 5、意大利 4、美国 2、中国香港 1（共 100 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics12.2%
- Traditional Chinese Medicine AnalysisMedicine8%
- Natural Antidiabetic Agents StudiesMedicine6.3%
- Natural product bioactivities and synthesisBiochemistry, Genetics and Molecular Biology6.1%
- Phytochemicals and Antioxidant ActivitiesMedicine5.4%
- Phytochemistry and Biological ActivitiesAgricultural and Biological Sciences4.7%
- Traditional Chinese Medicine StudiesMedicine4.7%
- Ginseng Biological Effects and ApplicationsBiochemistry, Genetics and Molecular Biology4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
CiteScore出版商官网
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布）
- 12.2出版商官网 ·
- CiteScore 2026-06
- 5.7LetPub ·
- CiteScore（出版商公布）
- 5.7出版商官网 ·
- SJR 2026-06
- 0.56LetPub ·
- SNIP 2026-06
- 0.81LetPub ·
- h-index
- 33OpenAlex ·
- i10-index
- 177OpenAlex ·
- 两年平均被引
- 3.76OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 829 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 119 | 119 | 52 |
| 2025 | 166 | 166 | 375 |
| 2024 | 211 | 211 | 1,439 |
| 2023 | 135 | 135 | 1,556 |
| 2022 | 163 | 163 | 1,523 |
| 2021 | 35 | 35 | 412 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
出版商公布的审稿周期 期刊官网自述数据
64 天投稿到接收 · 投稿社区反馈约 10 周
出版商统计口径以官网为准；本刊近 24 个月的文章日期尚未获得，因此以官方数据为准。
各来源数据
- 平均审稿速度（社区反馈）
- 10 WeeksLetPub ·
- 投稿到首次决定
- 2 天出版商官网 ·
- 外审后首次决定
- 27 天出版商官网 ·
- 投稿到接收
- 64 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 11 周DOAJ ·
- 评审方式
- 双盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
钻石开放获取（无 APC）DOAJ
所有文章开放获取，且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 1,550 / EUR 1,450 / GBP 1,240 / JPY 192,250 | — | — | |
| LetPub | USD 1,400 | 有 | — | |
| 出版商官网 | USD 2,380 | — | — |
其他费用与减免（作者指南）
- 其他费用
- 收取，金额见官网
- 版面费
- 收取，金额见官网
- 投稿费
- 收取，金额见官网
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点5 项，摘自作者指南
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 推荐审稿人
- 必须提供
- Highlights（研究亮点）
- 可选
- 图文摘要
- 必须提供
- 不接收
- case reports
接收的文章类型12 种
- case reportOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- graphical reviewsGraphical Reviews. These reviews will summarize schematically key concepts, established and novel ideas which will be accessible to a broad audience and freely …未说明篇幅
- letters to the editorLetters to the Editor on relevant issues of pharmacology or commenting on the literature published in this journal or in Pharmacological Research - Modern Chine…未说明篇幅
- meta-analysisOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- original articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- original articlesOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- regular paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- research paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- reviewOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- review articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- review articles and meta-analysesReview articles and meta-analyses. Review articles and meta-analyses are welcome but should be topical and not just an overview of the literature.未说明篇幅
- short communicationOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI in scientific writing
作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具的情况。 模型中文摘要
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Author contributions
为提高透明度，期刊要求通讯作者使用CRediT分类（包含14种角色）提供每位合著者对稿件的具体贡献。 模型中文摘要
For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration;…
原文 ↗出版商官网 ·- 利益冲突 Declaration of interest
所有作者必须披露任何可能不当影响其工作的财务和个人关系，并需在两处（利益声明摘要和详细的利益声明表）进行披露。 模型中文摘要
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
原文 ↗出版商官网 ·- 许可与版权 Copyright
文章被接收后，作者将被要求完成一份许可协议，开放获取文章的第三方再使用许可取决于作者选择的用户许可。 模型中文摘要
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
原文 ↗出版商官网 ·- 开放获取 Open Access
期刊开放获取出版信息请访问其开放获取页面。 模型中文摘要
Please visit our Open Access page for more information about open access publishing in this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
该期刊采用单盲同行评审流程，合适的稿件通常至少送交两名独立专家评审，编辑对稿件接收或拒绝拥有最终决定权。 模型中文摘要
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
原文 ↗出版商官网 ·- 预印本 Preprints
预印本可随时随地在任何地方共享，在预印本服务器上共享预印本不会被视为先前发表。 模型中文摘要
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- Netherlands
- 出版语言
- English
- ISSN
- 2667-1425
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Pharmacological Research Modern Chinese Medicine 的常见问题
Pharmacological Research Modern Chinese Medicine 的影响因子是多少？
期刊官网公布的影响因子为 12.2，属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 5.7，h-index 为 33。
Pharmacological Research Modern Chinese Medicine 的审稿周期多长？
出版商公布的投稿到接收时间约为 64 天；投稿社区反馈的平均审稿速度为约 10 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Pharmacological Research Modern Chinese Medicine 的投稿格式要求是什么？
据期刊作者指南：参考文献格式：顺序编码制（按引用顺序编号）；推荐审稿人：必须提供；Highlights：可选；图文摘要：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Pharmacological Research Modern Chinese Medicine 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 100 位编委中，中国大陆 85 位（约 85%）；人数最多的国家是 中国（85 位）、中国澳门（5 位）、意大利（4 位）。统计按编委会页面列出的机构国家计，仅供参考。
Pharmacological Research Modern Chinese Medicine 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Pharmacological Research Modern Chinese Medicine 被 Scopus、DOAJ 收录。
Pharmacological Research Modern Chinese Medicine 是开放获取期刊吗？版面费多少？
Pharmacological Research Modern Chinese Medicine 为钻石开放获取（无 APC）。不收取文章处理费。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。